Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
Repligen (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13-16 in San Francisco. Olivier Loeillot, President and CEO, will deliver a company overview presentation on Tuesday, January 14 at 1:30 p.m. PT.
The presentation will be accessible via live webcast through Repligen's Investor Relations website at www.repligen.com. A replay option will be available for a time after the event.
Repligen (NASDAQ:RGEN), leader nella tecnologia dei bioprocessi nel campo delle scienze della vita, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference in programma dal 13 al 16 gennaio a San Francisco. Olivier Loeillot, Presidente e CEO, presenterà una panoramica dell'azienda martedì 14 gennaio alle 13:30 PT.
La presentazione sarà accessibile tramite webcast live sul sito web delle Relazioni con gli Investitori di Repligen all'indirizzo www.repligen.com. Sarà disponibile un'opzione di riproduzione per un periodo dopo l'evento.
Repligen (NASDAQ:RGEN), líder en tecnología de bioprocesos en ciencias de la vida, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan, programada del 13 al 16 de enero en San Francisco. Olivier Loeillot, Presidente y CEO, ofrecerá una presentación sobre la empresa el martes 14 de enero a la 1:30 p.m. PT.
La presentación estará disponible a través de una transmisión en vivo en el sitio web de Relaciones con Inversores de Repligen en www.repligen.com. Habrá una opción de repetición disponible durante un tiempo después del evento.
Repligen (NASDAQ:RGEN), 생명 과학 분야의 생물 공정 기술 선도 기업,은 1월 13일부터 16일까지 샌프란시스코에서 열리는 제43회 JP모건 헬스케어 콘퍼런스에 참여한다고 발표했습니다. 올리비에 로유로, 사장 겸 CEO가 1월 14일 화요일 오후 1시 30분 PT에 회사 소개 프레젠테이션을 진행합니다.
프레젠테이션은 Repligen의 투자자 관계 웹사이트 www.repligen.com를 통해 실시간 웹캐스트로 제공될 예정입니다. 이벤트 후 일정 기간 동안 재생 옵션이 제공됩니다.
Repligen (NASDAQ:RGEN), leader en technologie de bioprocédés dans le domaine des sciences de la vie, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare prévue du 13 au 16 janvier à San Francisco. Olivier Loeillot, Président et CEO, fera une présentation de l'entreprise le mardi 14 janvier à 13h30 PT.
La présentation sera accessible en direct via webcast sur le site web des Relations Investisseurs de Repligen à l'adresse www.repligen.com. Une option de rediffusion sera disponible pendant un temps après l'événement.
Repligen (NASDAQ:RGEN), ein führendes Unternehmen in der Bioprozess-Technologie im Bereich der Lebenswissenschaften, hat seine Teilnahme an der 43. jährlichen JP Morgan Healthcare Conference angekündigt, die vom 13. bis 16. Januar in San Francisco stattfindet. Olivier Loeillot, Präsident und CEO, wird am Dienstag, den 14. Januar, um 13:30 Uhr PT eine Unternehmenspräsentation halten.
Die Präsentation wird über einen Livestream auf der Investor-Relations-Website von Repligen unter www.repligen.com zugänglich sein. Nach der Veranstaltung wird eine Wiedergabe-Option für eine gewisse Zeit verfügbar sein.
- None.
- None.
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT.
A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about our company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Sondra S. Newman
VP, Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
When is Repligen (RGEN) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Repligen's (RGEN) J.P. Morgan Healthcare Conference presentation?
What is the duration of the 2025 J.P. Morgan Healthcare Conference where RGEN is presenting?
Who will be presenting for Repligen (RGEN) at the 2025 J.P. Morgan Healthcare Conference?
